AHPA Asks FDA To Allow Firms To Route AER Contact To Offices Outside U.S.
This article was originally published in The Tan Sheet
Executive Summary
FDA's guidance on adverse event reporting for OTC drugs and dietary supplements should assure that firms operating outside the country can use U.S. addresses on their product labels but receive AER-related communication in their home countries, the American Herbal Products Association recommends
You may also be interested in...
Current MedWatch Form Stays While More Changes Could Occur Later In 2008
Substantive changes to FDA's MedWatch forms could come from the agency's MedWatch Plus program as soon as later this year
FDA Draft Guidance Fails To Deliver On AER Label Addresses – CSPI
The Center for Science in the Public Interest urges FDA to require complete addresses on OTC and supplement product labels for compliance with the adverse event reporting law that goes into effect Dec. 22
Supplement AER Draft Guidance Omits Answers, But Recognizes Complexities
FDA's draft guidance for dietary supplement adverse event reports encourages firms to employ health care professionals to take information from consumers and other sources of adverse event calls